VERU

VERU INC. (The Female Health Company) - 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for The Female Health Company (VERU Inc.) for the period ended March 31, 2011. The Company manufactures, markets, and distributes the FC2 female condom, the only FDA-approved product under a woman's control that provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including HIV/AIDS. The Company operates primarily in one segment and sells to public health sector organizations and commercial partners in 118 countries.

Key Financial Metrics

Liquidity: The Company generated net cash provided by operating activities of $2.54 million for the six months ended March 31, 2011. It maintains two lines of credit totaling $2.0 million with Heartland Bank, with no borrowings outstanding as of March 31, 2011.

Material Changes vs. Prior Period

• Revenue Decline: Net revenues decreased 40% ($2.9 million) for the quarter and 37% ($4.7 million) for the six months compared to the prior year periods. This was primarily due to a 32-34% decrease in unit volume caused by delays in the shipment of two large multi-million unit orders from public health sector purchasers (Brazil Ministry of Health and Republic of South Africa).
• Margin Compression: Gross profit margins declined from 58% to 42% (quarterly) and 58% to 48% (six-month) year-over-year. This was driven by reduced absorption of manufacturing overhead due to lower production volumes and a one-time production expense of $80,000.
• Expense Reduction: Operating expenses decreased significantly (25% quarterly, 46% six-month) compared to the prior year, largely because the prior year included one-time restructuring costs of $1.97 million related to the closure of the U.K. manufacturing facility. Selling, general, and administrative expenses also declined due to lower compensation and legal fees.
• Net Income: Net income decreased 96% for the quarter and 59% for the six months compared to the prior year, reflecting the revenue decline and margin compression.

Guidance, Outlook, and Risks

Outlook and Commentary: Management states that the revenue decline does not reflect a fundamental change in demand but rather the timing of large orders. The Company expects to utilize its net operating loss carryforwards in the future. A quarterly cash dividend of $0.05 per share was declared on April 11, 2011, payable May 10, 2011.

Risks and Contingencies:

• Single Product Reliance: The Company derives virtually all revenue from the FC2 female condom.
• Customer Concentration: Revenue is dependent on a limited number of large buyers (public health agencies and governments). Delays in tenders or procurement processes can cause significant quarter-to-quarter volatility.
• Regulatory Risk: As a Class III medical device, FC2 is subject to FDA regulation. Failure to comply could result in suspension of approval or recalls.
• Capital Requirements: While current cash is deemed adequate for the next 12 months, the Company may need to raise additional capital or borrow against its credit facility to fund operations and dividends.

Key Facts for Investor Verification

• Order Timing: Verify the status of the delayed multi-million unit orders from Brazil and South Africa, as their realization is critical to near-term revenue recovery.
• Dividend Sustainability: Confirm the Company's ability to maintain the $0.05 quarterly dividend given the recent decline in net income and cash outflows for dividends ($2.8 million in the last six months).
• Manufacturing Capacity: Assess the utilization rates of the Malaysia and India facilities, as low volume currently negatively impacts gross margins due to fixed overhead absorption.
• Regulatory Compliance: Monitor FDA inspection results and any potential changes in regulatory requirements for Class III medical devices.